Government to back Bukwang’s anticancer drug development

Published: 2012-05-03 06:56:00

Updated: 2012-05-03 06:56:00

Bukwang Pharmaceutical Co. said Friday that its apatinib mesylate, an investigational cancer drug currently undergoing clinical trials, will receive the government support as part of a government program to cultivate blockbuster drugs, targeting the international market.

Apatinib is a potential targeted treatment for metastatic gastric carcinoma, metastatic breast cancer and advanced hepatoc...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.